Australia

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

Lead Product(s): Eftilagimod Alpha,Oxaliplatin

Therapeutic Area: Oncology Product Name: IMP321

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2021

Details:

The new patent protects Immutep’s intellectual property relating to combination therapy comprising lead active immunotherapy candidate eftilagimod alpha, a LAG-3 fusion protein, and chemotherapy agent, specifically oxaliplatin, carboplatin, or topotecan.

Starpharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Starpharma Signs DEP® ADC Research Agreement with MSD

Lead Product(s): Dendrimer based antibody drug conjugates

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 12, 2021

Details:

Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.